Janssen’s Stelara has shown positive results in an ulcerative colitis (UC) trial, setting up a potential new indication for the inflammatory diseases drug.
Novartis’ developmental sickle cell disease drug crizanlizumab cut occurrences of a serious complication of the disease that can lead to irreversible or fatal organ damage, according to mid
Eli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with established rivals from Pfizer and Novartis.